Biomarkers in Drug Design
\r\n The discovery and evaluation of any novel biomarkers will ideally be specialized to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, so as to ensure accuracy and reproducibility of laboratory procedures. Predictive biomarkers indicate the likelihood of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers include both tumor-specific and surrogate biomarkers, and are crucial to accelerating the drug development process
\r\n\r\n
\r\n- Biomarker Discovery for Immuno-Oncology Agents
- Biomarkers in Drug Design & Clinical Trial
- Dose-Selection Biomarkers
- Biomarkers of Toxicity & Pharmacology
- Biomarkers of Efficacy
Related Conference of Biomarkers in Drug Design
Biomarkers in Drug Design Conference Speakers
Recommended Sessions
- Advancements in Drug Metabolism
- Biomarkers in Drug Design
- Chemoinformatic Drug Discovery
- Clinical Trails & Biotherapeutics
- Computer Aided Drug Design-CADD
- Drug Design And Development
- Drug Designing
- Drug Target Discovery
- Innovative Drug Discovery and Nanotechnology
- Medicinal Chemistry in Drug Discovery
- Novel Drug Delivery System in pharmaceutics
- Novel Drug Target Approaches
- Pharmaceutical Drug Discovery and Nanotechnology
- Pharmaceutical Research & Development
- Pharmacovigilance
- Proteomics & Bioinformatics in Drug Discovery